Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: May 26, 2022

Paragraph IV Challenges

✉ Email this page to a colleague

« Back to Dashboard

Tradename Dosage Generic Name NDA ANDAs Submitted 180 Day Exclusivity Status Submissiondate
ENVARSUS XR Extended-release Tablets tacrolimus 206406 1 2022-03-31
VYZULTA Ophthalmic Solution latanoprostene bunod 207795 1 2022-03-31
NUVESSA Vaginal Gel metronidazole 205223 1 2022-03-30
ZYDELIG Tablets idelalisib 205858 1 2022-03-23
ZTLIDO Topical Patch lidocaine 207962 1 2022-03-17
CYCLOPHOSPHAMIDE Injection cyclophosphamide 212501 1 2022-03-07
>Tradename >Dosage >Generic Name >NDA >180 Day Exclusivity Status >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.